Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

Description

The purpose of the study is to see if using an investigational drug called \[18F\]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a treatment study. The results of this study will not change a patient's clinical treatment plan but it may help physicians and researchers better understand how best to treat patients with breast cancer in the future.

Conditions

HER2-positive Breast Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the study is to see if using an investigational drug called \[18F\]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a treatment study. The results of this study will not change a patient's clinical treatment plan but it may help physicians and researchers better understand how best to treat patients with breast cancer in the future.

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

Condition
HER2-positive Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Birmingham

The University of Alabama at Birmingham, Birmingham, Alabama, United States, 35249

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patients must be ≥ 18 years old and ≤ 75 years old
  • 2. HER2+ breast cancer determined on primary tumor by a local pathology laboratory and defined as IHC score 3+ and/or positive by ISH (defined by ISH ratio of ≥ 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies). Only one positive result is required for eligibility
  • 3. Locally advanced stage II-III HER2+ breast cancer patients eligible for neoadjuvant therapy who are naïve to beginning treatment
  • 4. Estimated life expectancy of greater than one year
  • 5. Patients must have one lesion with RECIST measurable disease (great than 1 cm in diameter)
  • 1. Inability to provide informed consent F
  • 2. Weight over 350 lbs., due to the scanner bore size
  • 3. Lactating, known or suspected pregnancy. Women with child-bearing potential must a have a negative serum β-hCG pregnancy test within 48 hours or a negative urine β-hCG pregnancy test within 48 hours of each PET imaging study.
  • 4. Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)
  • 5. Unable to lie still on the imaging table for one (1) hour
  • 6. contraindication for gadolinium-based contrast agent, ProHance (gadoteridol)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Alabama at Birmingham,

Jonathan McConathy, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham

Study Record Dates

2027-08